日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm

Pivekimab Sunirine 治疗浆细胞样树突状细胞肿瘤

Pemmaraju, Naveen; Marconi, Giovanni; Montesinos, Pau; Lane, Andrew A; Mazzarella, Luca; Sallman, David A; Ulrickson, Matthew L; Schiller, Gary J; Erba, Harry P; Wang, Eunice S; Walter, Roland B; Deconinck, Eric; Aribi, Ahmed; Legrand, Ollivier; Lebon, Delphine; Maisano, Valerio; Martinelli, Giovanni; DeAngelo, Daniel J; Derenzini, Enrico; Du, Yining; Lakshmikanthan, Sribalaji; Potluri, Jalaja; Kantarjian, Hagop M; Daver, Naval G

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

结合突变和细胞遗传学特征的急性髓系白血病预后模型(采用维奈托克和去甲基化药物治疗)

Drekolias, Dimitrios; Tuz Zahra, Fatima; Fileni, Caroline; Sallman, David A; Mo, Qianxing; Chan, Onyee; Zhang, Ling; Vincelette, Nicole D; Yu, Xiaoqing; Sammut, Rinzine; Moon, Jungwon; Park, Junyoung; Umasangtongkul, Sura-Attha; Lledo, Felyschia M; Razabdouski, Tiffany N; Cheng, Chia-Ho; Qin, Dahui; Mai, Kathy; Ball, Somedeb; Shallis, Rory M; Xie, Zhuoer; Kuykendall, Andrew T; Padron, Eric; Sweet, Kendra; Walker, Alison R; Komrokji, Rami S; Lancet, Jeffrey E; Niyongere, Sandrine; Cluzeau, Thomas; Yun, Seongseok

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes

移植后采用TP53双链测序进行微小残留病(MRD)监测,并结合APR-246+阿扎胞苷维持治疗,可预测预后。

Sallman, David A; McLemore, Amy F; Komrokji, Rami; Elmariah, Hany; Kuykendall, Andrew T; Bejanyan, Nelli; Chan, Onyee; Faramand, Rawan; Pidala, Joseph; Yoder, Sean J; Perez, Lia; Nishihori, Taiga; Padron, Eric; Fernandez, Hugo; Lancet, Jeffrey E; Mishra, Asmita

Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

TP53突变型髓系肿瘤中5号染色体畸变的特征分析(原始细胞≥5%):一项国际TP53研究者网络(iTiN)研究

Yasin, Irfan; Stengel, Anna; Shao, Haipeng; Kaur, Amandeep; Mason, Emily F; Patwardhan, Pranav P; Bailey, Nathanael G; Ghosh, Sharmila; Inamdar, Kedar V; Patel, Anand A; Pandiri, Madhavi; Zhang, Jingjing; Sojitra, Payal; Tariq, Hamza; Pan, Zenggang; Wiredja, Danica; Wang, Peng; Tjota, Melissa Y; Segal, Jeremy P; Chang, Hong; Sallman, David A; Arber, Daniel A; Tefferi, Ayalew; Badar, Talha; Perry, Anamarija M; Haferlach, Claudia; Lager, Angela M; Venkataraman, Girish

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics

HMA联合维奈托克与强化化疗治疗极高危细胞遗传学AML的疗效比较

Aguirre, Luis E; Bewersdorf, Jan Philipp; Liu, Yiwen; Shallis, Rory M; Boussi, Leora; Zucenka, Andrius; Garciaz, Sylvain; Bystrom, Rebecca P; DeAngelo, Daniel J; Stone, Richard M; Luskin, Marlise R; Garcia, Jacqueline S; Winer, Eric S; Ling, Kelly; Chen, Evan C; Wadleigh, Martha; Berton, Guillaume; Stein, Eytan M; Goldberg, Aaron D; Mendez, Lourdes; Zeidan, Amer M; Sallman, David A; Shimony, Shai; Stahl, Maximilian

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

骨髓增生异常综合征患者p53功能障碍的特征及临床意义

Zampini, Matteo; Riva, Elena; Lanino, Luca; Sauta, Elisabetta; Antunes Dos Reis, Rita; Ejarque, Rosa Maria Andres; Maggioni, Giulia; Termanini, Alberto; Merlotti, Alessandra; Campagna, Alessia; Dall'Olio, Lorenzo; Kulasekararaj, Austin; Calvi, Michela; Di Vito, Clara; Bonometti, Arturo; Rahal, Daoud; Croci, Giorgio; Boveri, Emanuela; Gianelli, Umberto; Ponzoni, Maurilio; Caselli, Rossella; Albertazzi, Serena; Todisco, Gabriele; Ubezio, Marta; Crisafulli, Laura; Frigo, Alessandro; Lugli, Enrico; Mosca, Ettore; Acha, Pamela; Ghisletti, Serena; Nicassio, Francesco; Santoro, Armando; Diez-Campelo, Maria; Solé, Francesc; Ades, Lionel; Platzbecker, Uwe; Santini, Valeria; Fenaux, Pierre; Haferlach, Torsten; Sallman, David; Garcia-Manero, Guillermo; Mavilio, Domenico; Remondini, Daniel; Castellani, Gastone; D'Amico, Saverio; Zeidan, Amer M; Komrokji, Rami; Kordasti, Shahram; Ficara, Francesca; Della Porta, Matteo Giovanni

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Magrolimab联合阿扎胞苷与医生选择方案治疗未经治疗的TP53突变型急性髓系白血病:ENHANCE-2研究

Zeidner, Joshua F; Sallman, David A; Récher, Christian; Daver, Naval G; Leung, Anskar Y H; Hiwase, Devendra K; Subklewe, Marion; Pabst, Thomas; Montesinos, Pau; Larson, Richard A; Wilde, Lindsay; Enjeti, Anoop K; Kawashima, Ichiro; Papayannidis, Cristina; O'Nions, Jenny; Johnson, Lisa; Dong, Mei; Huang, Julie; Bagheri, Taravat; Hacohen Kleiman, Gal; Lee, Calvin; Vyas, Paresh

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

降低MDS患者参与临床试验的门槛:icMDS立场声明

Borate, Uma; Pugh, Kelly; Waller, Allyson; Welkie, Rina Li; Huang, Ying; Bewersdorf, Jan Philipp; Stahl, Maximilian; DeZern, Amy E; Platzbecker, Uwe; Sekeres, Mikkael A; Wei, Andrew H; Buckstein, Rena J; Roboz, Gail J; Savona, Michael R; Loghavi, Sanam; Hasserjian, Robert P; Fenaux, Pierre; Sallman, David A; Hourigan, Christopher S; Della Porta, Matteo Giovanni; Nimer, Stephen; Little, Richard F; Santini, Valeria; Efficace, Fabio; Taylor, Justin; Garcia-Manero, Guillermo; Odenike, Olatoyosi; Kim, Tae Kon; Halene, Stephanie; Komrokji, Rami S; Griffiths, Elizabeth A; Greenberg, Peter L; Xu, Mina L; Xie, Zhuoer; Bejar, Rafael; Sanz, Guillermo F; Patnaik, Mrinal M; Figueroa, Maria; Carraway, Hetty E; Abdel-Wahab, Omar; Starczynowski, Daniel; Padron, Eric; Boultwood, Jacqueline; Gore, Steven; Daver, Naval G; Churpek, Jane E; Majeti, Ravindra; Bennett, John M; List, Alan F; Brunner, Andrew M; Zeidan, Amer M

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

长期随访及eprenetapopt联合阿扎胞苷治疗TP53突变型MDS/AML患者的II期联合试验结果

Sallman, David A; Komrokji, Rami S; Dezern, Amy E; Sebert, Marie; Garcia-Manero, Guillermo; Rahmé, Ramy; Winer, Eric S; Lehmann-Che, Jacqueline; Roboz, Gail J; Madelaine, Isabelle; Sekeres, Mikkael A; Peterlin, Pierre; Chan, Onyee; Beyne-Rauzy, Odile; Kuykendall, Andrew; Recher, Christian; McLemore, Amy; Stamatoullas, Aspasia; Zhang, Ling; Willems, Lise; Mo, Qianxing; Raffoux, Emmanuel; Nardelli, Lisa; Berthon, Céline; Al Ali, Najla H; Quesnel, Bruno; Padron, Eric; Kantarjian, Hagop M; List, Alan F; Ades, Lionel; Lancet, Jeffrey E; Fenaux, Pierre; Cluzeau, Thomas

Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS

在真实世界中,对鲁帕西普的反应可以预测,并且能够改善低危骨髓增生异常综合征(LR-MDS)患者的总体生存期。

Consagra, Angela; Lanino, Luca; Al Ali, Najla H; Aguirre, Luis; Xie, Zhuoer; Chan, Onyee; Andreossi, Gloria; Raddi, Marco G; Rigodanza, Luca; Sanna, Alessandro; Mattiuz, Giorgio; Tofacchi, Elena; Amato, Cristina; Tanturli, Michele; De Pourcq, Sven; Walker, Alison; Kuykendall, Andrew; Lancet, Jeffrey; Padron, Eric; Sallman, David A; Restuccia, Francesco; Perego, Alessandra; Ubezio, Marta; Fattizzo, Bruno; Riva, Marta; Maggioni, Giulia; Campagna, Alessia; Della Porta, Matteo G; Santini, Valeria; Komrokji, Rami S